Ferrari SL et al. |
Bone response to intermittent parathyroid hormone is altered in mice null for {beta}-Arrestin2. |
2005 |
Endocrinology |
pmid:15705780
|
Heymann D et al. |
Osteolytic bone diseases: physiological analogues of bone resorption effectors as alternative therapeutic tools. |
2005 |
Drug Discov. Today |
pmid:15708742
|
Mezquita-Raya P et al. |
The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women. |
2005 |
Osteoporos Int |
pmid:15711777
|
Pantouli E et al. |
Inflammatory cytokines activate p38 MAPK to induce osteoprotegerin synthesis by MG-63 cells. |
2005 |
Biochem. Biophys. Res. Commun. |
pmid:15721297
|
Korcok J et al. |
P2Y6 nucleotide receptors activate NF-kappaB and increase survival of osteoclasts. |
2005 |
J. Biol. Chem. |
pmid:15722352
|
Bock O et al. |
Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders. |
2005 |
J. Pathol. |
pmid:15726648
|
Mosheimer BA et al. |
Syndecan-1 is involved in osteoprotegerin-induced chemotaxis in human peripheral blood monocytes. |
2005 |
J. Clin. Endocrinol. Metab. |
pmid:15728209
|
Han KO et al. |
The changes in circulating osteoprotegerin after hormone therapy in postmenopausal women and their relationship with oestrogen responsiveness on bone. |
2005 |
Clin. Endocrinol. (Oxf) |
pmid:15730418
|
Xiao XH et al. |
[Ascorbic acid inhibits the formation and function of osteoclasts from RAW264.7 cells induced by receptor activated nuclear factor kappaB ligand in vitro]. |
2004 |
Zhonghua Yi Xue Za Zhi |
pmid:15730627
|
Tiranathanagul S et al. |
Actinobacillus actinomycetemcomitans lipopolysaccharide activates matrix metalloproteinase-2 and increases receptor activator of nuclear factor-kappaB ligand expression in human periodontal ligament cells. |
2004 |
J. Periodontol. |
pmid:15732867
|
Schneider HG and Sentry J |
Multiple myeloma. |
2005 |
N. Engl. J. Med. |
pmid:15736296
|
Ambroszkiewicz J et al. |
[Biochemical bone resorption markers in children with osteosarcoma]. |
2004 Apr-Jun |
Med Wieku Rozwoj |
pmid:15738598
|
Skládal P et al. |
Investigation of osteoprotegerin interactions with ligands and antibodies using piezoelectric biosensors. |
2005 |
Biosens Bioelectron |
pmid:15741072
|
Kanno T et al. |
Platelet-rich plasma enhances human osteoblast-like cell proliferation and differentiation. |
2005 |
J. Oral Maxillofac. Surg. |
pmid:15742288
|
Mazziotti G et al. |
Recombinant human TSH modulates in vivo C-telopeptides of type-1 collagen and bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal women monitored for differentiated thyroid carcinoma. |
2005 |
J. Bone Miner. Res. |
pmid:15746993
|
Corey E et al. |
Osteoprotegerin in prostate cancer bone metastasis. |
2005 |
Cancer Res. |
pmid:15753366
|
Moschen AR et al. |
The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. |
2005 |
Gut |
pmid:15753532
|
Nagasaki T et al. |
Increased levels of serum osteoprotegerin in hypothyroid patients and its normalization with restoration of normal thyroid function. |
2005 |
Eur. J. Endocrinol. |
pmid:15757850
|
Kostenuik PJ |
Revisiting the seed and soil theory of bone metastasis: new tools, same answer. |
2004 |
J Musculoskelet Neuronal Interact |
pmid:15758267
|
Simmons CA et al. |
Spatial heterogeneity of endothelial phenotypes correlates with side-specific vulnerability to calcification in normal porcine aortic valves. |
2005 |
Circ. Res. |
pmid:15761200
|
Gallant MA et al. |
Production of prostaglandin D(2) by human osteoblasts and modulation of osteoprotegerin, RANKL, and cellular migration by DP and CRTH2 receptors. |
2005 |
J. Bone Miner. Res. |
pmid:15765187
|
Mandelin J et al. |
Pseudosynovial fluid from loosened total hip prosthesis induces osteoclast formation. |
2005 |
J. Biomed. Mater. Res. Part B Appl. Biomater. |
pmid:15768436
|
Crisafulli A et al. |
Effects of the phytoestrogen genistein on cardiovascular risk factors in postmenopausal women. |
2005 |
Menopause |
pmid:15772566
|
Mizuno N et al. |
Characterization of epithelial cells derived from periodontal ligament by gene expression patterns of bone-related and enamel proteins. |
2005 |
Cell Biol. Int. |
pmid:15774307
|
Indridason OS et al. |
Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover. |
2005 |
Osteoporos Int |
pmid:15776220
|
Voskaridou E and Terpos E |
Osteoprotegerin to soluble receptor activator of nuclear factor kappa-B ligand ratio is reduced in patients with thalassaemia-related osteoporosis who receive vitamin D3. |
2005 |
Eur. J. Haematol. |
pmid:15777350
|
Mossetti G et al. |
Interleukin-6 and osteoprotegerin systems in Paget's disease of bone: relationship to risedronate treatment. |
2005 |
Bone |
pmid:15777635
|
Janssens K et al. |
An intermediate form of juvenile Paget's disease caused by a truncating TNFRSF11B mutation. |
2005 |
Bone |
pmid:15777670
|
Fábrega E et al. |
Osteoprotegerin and RANKL in alcoholic liver cirrhosis. |
2005 |
Liver Int. |
pmid:15780054
|
Fukushima H et al. |
IL-1-induced receptor activator of NF-kappa B ligand in human periodontal ligament cells involves ERK-dependent PGE2 production. |
2005 |
Bone |
pmid:15780952
|
Regmi A et al. |
Suramin interacts with RANK and inhibits RANKL-induced osteoclast differentiation. |
2005 |
Bone |
pmid:15780954
|
Abrahamsen B et al. |
Circulating amounts of osteoprotegerin and RANK ligand: genetic influence and relationship with BMD assessed in female twins. |
2005 |
Bone |
pmid:15781001
|
Zhao HY et al. |
The influence of Lys3Asn polymorphism in the osteoprotegerin gene on bone mineral density in Chinese postmenopausal women. |
2005 |
Osteoporos Int |
pmid:15782282
|
Bezerra MC et al. |
RANK, RANKL and osteoprotegerin in arthritic bone loss. |
2005 |
Braz. J. Med. Biol. Res. |
pmid:15785827
|
Stilgren LS et al. |
[The cytokine system of bone tissue]. |
2005 |
Ugeskr. Laeg. |
pmid:15789838
|
Fukushima H et al. |
Parathyroid-hormone-related protein induces expression of receptor activator of NF-{kappa}B ligand in human periodontal ligament cells via a cAMP/protein kinase A-independent pathway. |
2005 |
J. Dent. Res. |
pmid:15790738
|
Konduri K et al. |
Immunoglobulin M myeloma: evaluation of molecular features and cytokine expression. |
2005 |
Clin Lymphoma |
pmid:15794867
|
Bord S et al. |
Megakaryocytes modulate osteoblast synthesis of type-l collagen, osteoprotegerin, and RANKL. |
2005 |
Bone |
pmid:15794927
|
Giuliani N et al. |
Update on the pathogenesis of osteolysis in multiple myeloma patients. |
2004 |
Acta Biomed |
pmid:15796087
|
Contractor T et al. |
Osteoclasts resorb protein-free mineral (Osteologic discs) efficiently in the absence of osteopontin. |
2005 Mar-Apr |
In Vivo |
pmid:15796195
|
Zannettino AC et al. |
Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor. |
2005 |
J. Cell. Physiol. |
pmid:15799029
|
Tada T et al. |
Oral squamous cell carcinoma cells induce osteoclast differentiation by suppression of osteoprotegerin expression in osteoblasts. |
2005 |
Int. J. Cancer |
pmid:15800904
|
Mandelin J et al. |
Interface tissue fibroblasts from loose total hip replacement prosthesis produce receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and cathepsin K. |
2005 |
J. Rheumatol. |
pmid:15801030
|
Holmen SL et al. |
Essential role of beta-catenin in postnatal bone acquisition. |
2005 |
J. Biol. Chem. |
pmid:15802266
|
Bernstein CN et al. |
Serum osteoprotegerin is increased in Crohn's disease: a population-based case control study. |
2005 |
Inflamm. Bowel Dis. |
pmid:15803021
|
Mitani M et al. |
Estrogen specifically stimulates expression and production of osteoprotegerin from rheumatoid synovial fibroblasts. |
2005 |
Int. J. Mol. Med. |
pmid:15806305
|
Ling LJ et al. |
Areca nut extracts modulated expression of alkaline phosphatase and receptor activator of nuclear factor kappaB ligand in osteoblasts. |
2005 |
J. Clin. Periodontol. |
pmid:15811051
|
Maïmoun L et al. |
Changes in osteoprotegerin/RANKL system, bone mineral density, and bone biochemicals markers in patients with recent spinal cord injury. |
2005 |
Calcif. Tissue Int. |
pmid:15812577
|
Ulrich-Vinther M and Andreassen TT |
Osteoprotegerin treatment impairs remodeling and apparent material properties of callus tissue without influencing structural fracture strength. |
2005 |
Calcif. Tissue Int. |
pmid:15812581
|
Ishizuka K et al. |
Inhibitory effect of CGRP on osteoclast formation by mouse bone marrow cells treated with isoproterenol. |
2005 |
Neurosci. Lett. |
pmid:15814197
|
Cui N et al. |
Effect of YM529 on a model of mandibular invasion by oral squamous cell carcinoma in mice. |
2005 |
Clin. Cancer Res. |
pmid:15814653
|
Gorczynski RM et al. |
Neutral buoyancy and sleep-deprived serum factors alter expression of cytokines regulating osteogenesis. |
2005 May-Jun |
Acta Astronaut |
pmid:15835039
|
Essalihi R et al. |
Phenotypic modulation of vascular smooth muscle cells during medial arterial calcification: a role for endothelin? |
2004 |
J. Cardiovasc. Pharmacol. |
pmid:15838266
|
Morony S et al. |
The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy. |
2005 |
Endocrinology |
pmid:15845617
|
Rhee EJ et al. |
The effects of C161-->T polymorphisms in exon 6 of peroxisome proliferator-activated receptor-gamma gene on bone mineral metabolism and serum osteoprotegerin levels in healthy middle-aged women. |
2005 |
Am. J. Obstet. Gynecol. |
pmid:15846185
|
Mahamed DA et al. |
G(-) anaerobes-reactive CD4+ T-cells trigger RANKL-mediated enhanced alveolar bone loss in diabetic NOD mice. |
2005 |
Diabetes |
pmid:15855336
|
Leder BZ and Finkelstein JS |
Effect of aromatase inhibition on bone metabolism in elderly hypogonadal men. |
2005 |
Osteoporos Int |
pmid:15856361
|
Galli C et al. |
Comparison of human mandibular osteoblasts grown on two commercially available titanium implant surfaces. |
2005 |
J. Periodontol. |
pmid:15857069
|
Suzuki K et al. |
Osteoclastic function is accelerated in male patients with type 2 diabetes mellitus: the preventive role of osteoclastogenesis inhibitory factor/osteoprotegerin (OCIF/OPG) on the decrease of bone mineral density. |
2005 |
Diabetes Res. Clin. Pract. |
pmid:15860239
|
Glass DA et al. |
Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. |
2005 |
Dev. Cell |
pmid:15866165
|
Valenta A et al. |
Combined treatment with PTH (1-34) and OPG increases bone volume and uniformity of mineralization in aged ovariectomized rats. |
2005 |
Bone |
pmid:15869920
|
Chan MH et al. |
Specific biochemical markers of bone metabolism and cytokine study confirm the diagnosis of malignant infantile osteopetrosis at birth using cord blood sample. |
2005 |
Pathology |
pmid:15875734
|
Seminari E et al. |
Osteoprotegerin and bone turnover markers in heavily pretreated HIV-infected patients. |
2005 |
HIV Med. |
pmid:15876279
|
Schett G et al. |
Additive bone-protective effects of anabolic treatment when used in conjunction with RANKL and tumor necrosis factor inhibition in two rat arthritis models. |
2005 |
Arthritis Rheum. |
pmid:15880601
|
Moe SM et al. |
Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). |
2005 |
Kidney Int. |
pmid:15882271
|
Ueland T et al. |
Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. |
2005 |
Circulation |
pmid:15883214
|
Sabokbar A et al. |
Arthroplasty membrane-derived fibroblasts directly induce osteoclast formation and osteolysis in aseptic loosening. |
2005 |
J. Orthop. Res. |
pmid:15885469
|
Skoumal M et al. |
Osteoprotegerin and the receptor activator of NF-kappa B ligand in the serum and synovial fluid. A comparison of patients with longstanding rheumatoid arthritis and osteoarthritis. |
2005 |
Rheumatol. Int. |
pmid:15889303
|
Inoue H et al. |
Prostate cancer mediates osteoclastogenesis through two different pathways. |
2005 |
Cancer Lett. |
pmid:15890244
|
Lynch CC et al. |
MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. |
2005 |
Cancer Cell |
pmid:15894268
|
Choi BK et al. |
Prostaglandin E(2) is a main mediator in receptor activator of nuclear factor-kappaB ligand-dependent osteoclastogenesis induced by Porphyromonas gingivalis, Treponema denticola, and Treponema socranskii. |
2005 |
J. Periodontol. |
pmid:15898943
|
Carda C et al. |
Osteoprotegerin (OPG) and RANKL expression and distribution in developing human craniomandibular joint. |
2005 |
Tissue Cell |
pmid:15899507
|
Chang K et al. |
Pulsed electromagnetic fields stimulation affects osteoclast formation by modulation of osteoprotegerin, RANK ligand and macrophage colony-stimulating factor. |
2005 |
J. Orthop. Res. |
pmid:15913941
|
Depil S et al. |
Evaluation and prognostic value of serum osteoprotegerin in multiple myeloma. |
2005 |
Br. J. Haematol. |
pmid:15916694
|
Rasmussen LM and Ledet T |
Osteoprotegerin and diabetic macroangiopathy. |
2005 |
Horm. Metab. Res. |
pmid:15918117
|
Tanabe N et al. |
IL-1 alpha stimulates the formation of osteoclast-like cells by increasing M-CSF and PGE2 production and decreasing OPG production by osteoblasts. |
2005 |
Life Sci. |
pmid:15921993
|
Crisafulli A et al. |
Serum levels of osteoprotegerin and RANKL in patients with ST elevation acute myocardial infarction. |
2005 |
Clin. Sci. |
pmid:15926884
|
Koh JM et al. |
Alpha-lipoic acid suppresses osteoclastogenesis despite increasing the receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio in human bone marrow stromal cells. |
2005 |
J. Endocrinol. |
pmid:15930166
|
Bhattacharya A et al. |
Inhibition of osteoporosis in autoimmune disease prone MRL/Mpj-Fas(lpr) mice by N-3 fatty acids. |
2005 |
J Am Coll Nutr |
pmid:15930486
|
Buemi M et al. |
Osteoprotegerin, IL-6, IL-1, TNF-alpha and TGF-beta concentrations during acetate-free biofiltration. |
2005 Mar-Apr |
J. Nephrol. |
pmid:15931642
|
Kerschan-Schindl K et al. |
Serum levels of cathepsin K decrease with age in both women and men. |
2005 |
Exp. Gerontol. |
pmid:15935595
|
Ugur-Altun B et al. |
The relationship between insulin resistance assessed by HOMA-IR and serum osteoprotegerin levels in obesity. |
2005 |
Diabetes Res. Clin. Pract. |
pmid:15936463
|
Moran CS et al. |
Association of osteoprotegerin with human abdominal aortic aneurysm progression. |
2005 |
Circulation |
pmid:15939823
|
Li F et al. |
Annexin II stimulates RANKL expression through MAPK. |
2005 |
J. Bone Miner. Res. |
pmid:15940368
|
Sen O et al. |
The relation between serum levels of osteoprotegerin and postoperative epidural fibrosis in patients who underwent surgery for lumbar disc herniation. |
2005 |
Neurol. Res. |
pmid:15949247
|
Saunders MM et al. |
Mechanical stimulation effects on functional end effectors in osteoblastic MG-63 cells. |
2006 |
J Biomech |
pmid:15953606
|
Liu JZ et al. |
[Construction and biological activity study of human osteoprotegerin expressing adenoviral system]. |
2003 |
Sheng Wu Gong Cheng Xue Bao |
pmid:15969033
|
Liu JZ et al. |
[The OPG/RANKL/RANK system and bone resorptive disease]. |
2003 |
Sheng Wu Gong Cheng Xue Bao |
pmid:15971575
|
Frick KK et al. |
RANK ligand and TNF-alpha mediate acid-induced bone calcium efflux in vitro. |
2005 |
Am. J. Physiol. Renal Physiol. |
pmid:15972386
|
Lossdörfer S et al. |
PTH(1-34) affects osteoprotegerin production in human PDL cells in vitro. |
2005 |
J. Dent. Res. |
pmid:15972592
|
Arko B et al. |
Association of the osteoprotegerin gene polymorphisms with bone mineral density in postmenopausal women. |
2005 |
Maturitas |
pmid:15978970
|
Bock O et al. |
Osteosclerosis in advanced chronic idiopathic myelofibrosis is associated with endothelial overexpression of osteoprotegerin. |
2005 |
Br. J. Haematol. |
pmid:15982347
|
Fiore CE et al. |
Hepatitis C-associated osteosclerosis (HCAO): report of a new case with involvement of the OPG/RANKL system. |
2005 |
Osteoporos Int |
pmid:15983730
|
Amizuka N et al. |
Histological evaluation for "bone quality" on two mouse models with different bone remodeling. |
2005 |
J. Bone Miner. Metab. |
pmid:15984413
|
Ziegler S et al. |
Endurance running acutely raises plasma osteoprotegerin and lowers plasma receptor activator of nuclear factor kappa B ligand. |
2005 |
Metab. Clin. Exp. |
pmid:15988704
|
Yamada N et al. |
Down-regulation of osteoprotegerin production in bone marrow macrophages by macrophage colony-stimulating factor. |
2005 |
Cytokine |
pmid:15996478
|
Quinn JE et al. |
Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms. |
2005 |
Prostate Cancer Prostatic Dis. |
pmid:15999121
|
Mangashetti LS et al. |
IL-4 inhibits bone-resorbing activity of mature osteoclasts by affecting NF-kappa B and Ca2+ signaling. |
2005 |
J. Immunol. |
pmid:16002690
|
Whang PG et al. |
The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone. |
2005 |
J. Orthop. Res. |
pmid:16005175
|
Bashir A et al. |
Changes in RANKL/OPG/RANK gene expression in peripheral mononuclear cells following treatment with estrogen or raloxifene. |
2005 |
Steroids |
pmid:16005483
|